Shots:
- The MHRA has approved Wegovy pill (25mg, QD, PO) as an adjunct to lifestyle intervention for weight management in adults living with obesity or overweight, with ≥1 weight-related condition; launch is expected in select markets by H2’26
- Approval was based on the P-III (OASIS 4) trial assessing oral Wegovy vs PBO over 64wks. in 307 adults with obesity or overweight with ≥1 comorbidities
- OASIS 4 showed oral Wegovy resulted in 13.6% weight loss vs 2.4% with PBO after 64wks. in pts regardless of adherence, while in treatment- adherent adults, Wegovy achieved weight loss of 16.6% vs 2.7%
Ref: Globenewswire | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk Reports New STEP UP Trial Analyses on Wegovy 7.2mg for Weight Loss
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
